MedTrace Logo

Using Telehealth to Address Alcohol Misuse in HIV Care

NCT04546971 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2025-08-18

No results posted yet for this study

Summary

This project will test the effects of a telehealth counseling program on reducing alcohol use and improving HIV viral control among people with HIV who drink heavily. In total, 600 heavy drinkers with HIV will be assigned to either (a) a single session of brief counseling on alcohol use or (b) brief counseling plus referral to a telehealth counseling program that includes multiple sessions of counseling by videoconferencing and text messaging support. To understand the effects of the program, participants' alcohol use, HIV outcomes, and health will be assessed over a 2-year period.

Conditions

  • Alcohol Drinking
  • HIV Viremia

Interventions

BEHAVIORAL

Brief Intervention

Brief alcohol intervention delivered by telephone or videoconferencing focusing on advising participants to reduce drinking

BEHAVIORAL

Telehealth Counseling

5 sessions of counseling on alcohol use based on Motivational Interviewing.

BEHAVIORAL

Text messaging

A daily and then monthly text messaging program designed to help participants monitor drinking, set goals, and reinforce successful reduction or abstinence.

Sponsors & Collaborators

  • Brown University

    lead OTHER

Principal Investigators

  • Christopher Kahler, PhD · Brown University School of Public Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-22
Primary Completion
2026-04-15
Completion
2026-05-15

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04546971 on ClinicalTrials.gov